Evidence map›Paper›PMID 37969371›Full record

ArticleTranslational cancer research2023

Survival trends and conditional survival in primary non-metastatic esophageal cancer: a SEER population-based study and external validation.

Wei Sun, Xiaoyu Zhang, Zeting Qiu

Open access · diamondAbstract read
In one paragraph

Article in Translational cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Wei SunDepartment of Anesthesiology, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Xiaoyu ZhangDepartment of Thoracic Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Zeting QiuDepartment of Anesthesiology, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
First Affiliated Hospital of Shantou University Medical College · CNShantou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The dynamic survival trend of patients with primary non-metastatic esophageal cancer (nMEC) is unknown. We conducted a conditional survival (CS) analysis and developed a novel nomogram to predict it. Methods: Patients with primary nMEC were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Independent prognostic factors of cancer-specific survival (CSS) were identified. The log-rank test and Cox analysis were used to calculate probabilities of CS. We constructed nomograms to predict survival trends and CS probabilities based on the prognostic factors. Calibration curves and C-indexes were used for internal and external validation. Results: A total of 9,008 patients were identified from the SEER database and 37 patients were recruited as an external validation cohort. The 1- and 3-year CS rates were 69.6% and 43.1% at diagnosis, rising to 95.2% and 86.2% at the fifth conditional year. CS probabilities by different variables continuously improved over time. The calibration curves of the CS nomograms fit well. The C-indexes were 0.700 (95% CI: 0.693-0.709) in the training cohort, 0.693 (95% CI: 0.669-0.717) in the internal validation cohort, and 0.683 (95% CI: 0.556-0.810) in the external validation cohort. Conclusions: CS rates are more dynamic than traditional survival rates for patients surviving for a relatively longer period. The CS rates of patients with nMEC improved over time and became stable after surviving for a few years. We developed and validated nomograms to predict CS probabilities.

Indexed as

conditional survival (CS)nomogramnon-metastatic esophageal cancer (nMEC)Surveillance, Epidemiology, and End Results (SEER)Survival trend

Identifiers

PMID37969371
PMCPMC10643951
OpenAlexW4387955646

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.